Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport

Coen C. Paulusma, Annemiek Groen, Cindy Kunne, Kam S. Ho‐Mok, Astrid L. Spijkerboer, D. Rudi de Waart, Frans J. Hoek, Heleen Vreeling, Kees A. Hoeben, Jan van Marle, Ludmila Pawlikowska, Laura N. Bull, Alan F. Hofmann, A. S. Knisely, Ronald P. J. Oude Elferink – 23 June 2006 – Progressive familial intrahepatic cholestasis type 1 (PFIC1, Byler disease, OMIM 211600) is a severe inherited liver disease caused by mutations in ATP8B1. ATP8B1 is a member of the type 4 subfamily of P‐type ATPases, which are phospholipid flippases.

The natural history of hepatitis C virus in pediatric liver transplant recipients

Neal R. Barshes, Ian W. Udell, Timothy C. Lee, Christine A. O'Mahony, Saul J. Karpen, Beth A. Carter, John A. Goss – 23 June 2006 – Although rare in the pediatric population, the natural history of hepatitis C virus (HCV) recurrence in pediatric patients undergoing orthotopic liver transplantation (OLT) for end‐stage liver disease secondary to HCV has not been well described. We performed an analysis of all 67 pediatric patients (<17 years old) who have undergone OLT for HCV in the United States between 1/1988 and 6/2005. The 67 pediatric patients received a total of 83 OLTs for HCV.

Outcome of acute hepatitis C is related to virus‐specific CD4 function and maturation of antiviral memory CD8 responses

Simona Urbani, Barbara Amadei, Paola Fisicaro, Daniela Tola, Alessandra Orlandini, Luca Sacchelli, Cristina Mori, Gabriele Missale, Carlo Ferrari – 23 June 2006 – A timely, efficient, and coordinated activation of both CD4 and CD8 T cell subsets following HCV infection is believed to be essential for HCV control. However, to what extent a failure of the individual T cell subsets can contribute to the high propensity of HCV to persist is still largely undefined.

Different anti‐HCV profiles of statins and their potential for combination therapy with interferon

Masanori Ikeda, Ken‐ichi Abe, Masashi Yamada, Hiromichi Dansako, Kazuhito Naka, Nobuyuki Kato – 23 June 2006 – We recently developed a genome‐length hepatitis C virus (HCV) RNA replication system (OR6) with luciferase as a reporter. The OR6 assay system has enabled prompt and precise quantification of HCV RNA replication. Pegylated interferon (IFN) and ribavirin combination therapy is the world standard for chronic hepatitis C, but its effectiveness is limited to about 55% of patients. Newer therapeutic approaches are needed.

Subscribe to